Bird Flu > Bird Flu News > ChemoCentryx presents CCX140 clinical data at EASD Association

ChemoCentryx presents CCX140 clinical data at EASD Association
ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well ...